Starfish medical icon only logo
Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

The Hidden Costs of of Medical Device Sterilization

YouTube video thumbnail

When teams cost out a sterile disposable device, the obvious line items come first: parts, assembly, sterilization. Those three feel like the full picture. The hidden costs of medical device production suggest otherwise.

In this episode of Bio Break, Nick and Nigel breaks down what actually goes into the cost of getting a sterilized device into a user’s hands, and why up to 30% of costs can sit in places most teams don’t plan for.

Why the Obvious Costs Are Only Part of the Story

Parts have to travel to the assembly facility. Assembled devices have to travel to the sterilizer. Sterilized devices have to reach the distributor. The distributor ships to the customer. That is at least four separate shipping events before a product reaches anyone, each with its own cost, timing, and variability.

And then the invoices arrive a month later. Sometimes two months later. Sometimes with a tariff attached that nobody anticipated.

Where Hidden Costs in Sterile Device Manufacturing Start to Compound

Shipping is one part of it. But maintaining sterility between those steps adds another layer. Sterility validation requires ongoing checks. Clean rooms require continuous testing to maintain certification. Inspection, inventory management, and quality controls all sit underneath the headline numbers.

For terminal sterilization devices, which are typically disposable and sold in higher volumes, these costs compound with every unit. The math that looks reasonable at low volume looks very different at scale.

Why This Matters Before You Set Your Price

Understanding the full cost picture before a product reaches market is different from understanding it after. The gap between what a team plans for and what the actual cost of production turns out to be is where margin assumptions tend to break down.

The episode works through what that gap looks like in practice and what to account for before it becomes a problem.

What This Episode Cover

  • Why terminally sterilized, disposable devices carry a different cost structure than one-time-use products
  • The three visible cost categories in producing a sterilized device: parts, sterilization, and assembly
  • How much of total device cost can be hidden outside those three obvious categories
  • The number of separate shipping legs involved in getting a sterilized device to a customer
  • Why sterility validation and clean room certification are ongoing, recurring costs
  • Why planning for these hidden costs in advance protects realistic profit margins

Enjoying Bio Break? Sign up to get new episodes sent to your inbox.

Subscribe to Bio Break
Businessman holding a glowing compliance icon with legal and regulatory symbols, representing REACH SVHC compliance for medical device manufacturers

MPO: REACH SVHC Compliance for Medical Device Makers

Nigel Syrotuck breaks down REACH SVHC compliance for teams working with material suppliers and compliance questionnaires.

Medical Device Design Simulation

MD+DI: Medical Device Simulation Strategy That Works

We examine when computational modelling and simulation, or CM&S, genuinely supports medical device simulation strategy and when it becomes a costly detour.

Transparent medical device prototype surrounded by computational simulation mesh representing modeling and simulation during medical device development.

Building Better Medical Devices Faster: The Strategic Role of CM&S

Many teams still underuse CM&S, often bringing it late in device validation, when key decisions have already been made. That approach leaves much of the value of CM&S untapped.

Biomedical engineer reviewing a thermal simulation of human head tissue on a monitor, color-mapped from warm to cool gradients

Bioheat Transfer in Living Tissue: History, Models, and Engineering Applications

This article traces the Pennes bioheat equation from its 1948 origins to modern multiscale approaches, explaining how engineers select the right level of modelling complexity across device categories.